Dermira Gets a Buy Rating from Needham

By Austin Angelo

In a report issued on September 15, Alan Carr from Needham reiterated a Buy rating on Dermira (NASDAQ: DERM), with a price target of $46. The company’s shares closed on Friday at $26.29.

According to, Carr is a 4-star analyst with an average return of 7.3% and a 44.3% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on Dermira is Strong Buy and the average price target is $45.50, representing a 73.1% upside.

In a report issued on September 7, Cantor Fitzgerald also assigned a Buy rating to the stock with a $45 price target.

The company has a one year high of $38.75 and a one year low of $21.35. Currently, Dermira has an average volume of 416.8K.

Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DERM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Dermira, Inc. is a biopharmaceutical company that focuses on bringing differentiated products to dermatologists and patients. It also focuses on medical dermatology, a field that concentrates on therapeutic solutions to treat skin conditions, such as psoriasis, hyperhidrosis and acne. Dermira was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C.